Biotechnology News and Research

RSS

Research finding could have major implications for diabetes treatment

Harvard Stem Cell Institute researchers, representing five Harvard departments and affiliated institutions as well as the Massachusetts Institute of Technology, have demonstrated that adult cells, reprogrammed into another cell type in a living animal, can remain functional over a long period.

18 Nov 2014

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world’s leading medical journals, The Lancet Neurology.

18 Nov 2014

UT Southwestern researchers identify new gene mutations involved in certain kidney cancers

Using next generation gene sequencing techniques, cancer researchers at UT Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.

17 Nov 2014

Study underlines critical role of Fragile X mental retardation protein in brain development

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability (ID), as well as the most frequent monogenic cause of autism spectrum disorders (ASD). FXS is caused by the absence or incorrect production of the protein FMRP (Fragile X Mental Retardation Protein).

17 Nov 2014

EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF, has entered a collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers.

From EKF Diagnostics 17 Nov 2014

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc.

14 Nov 2014

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014.

14 Nov 2014

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

Load bearing, biodegradable implants can reduce the number of second surgeries

No other joint in the human body is as highly mobile as is the shoulder. However, it is also very sensitive and prone to injury, with athletes being particularly affected.

14 Nov 2014

Prosthetic retina could help counter the effects of AMD and related vision disorders

The loss of eyesight, often caused by retinal degeneration, is a life-altering health issue for many people, especially as they age.

13 Nov 2014

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Sulindac drug can protect against oxidative damage due to AMD

While oxygen is essential to our planet's life force and the way we function and stay healthy, high concentrations referred to as oxidative stress may very well be the cause of more than 70 widely-spread diseases such as cancer, heart disease, neurodegenerative diseases, and eye diseases including macular degeneration.

11 Nov 2014

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.

11 Nov 2014

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells.

7 Nov 2014

Applying lessons learnt from failed Alzheimer's studies for future research

Disappointing results in clinical Alzheimer's studies discourage doctors and scientists from continuing their research into ɣ-secretases and a possible treatment against Alzheimer's disease. In the prestigious journal Cell, the Alzheimer's expert Bart De Strooper (VIB-KU Leuven) argues that these studies are not pointless, but merely indicate what the next steps should be for the Alzheimer's research.

7 Nov 2014

Salk Institute researchers heal injured hearts of living mice

Researchers at the Salk Institute have healed injured hearts of living mice by reactivating long dormant molecular machinery found in the animals' cells, a finding that could help pave the way to new therapies for heart disorders in humans.

7 Nov 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014